阿哌沙班与华法林治疗静脉血栓栓塞症的有效性和安全性比较
本研究基于2014—2017年商业和Medicare补充数据库,对静脉血栓栓塞症(VTE)新使用者进行回顾性队列分析,采用倾向评分1:4匹配控制混杂。匹配后共纳入36,907例患者(阿哌沙班8,094例,华法林28,813例),阿哌沙班较华法林与更低的复发性VTE风险(HR 0.54;95%CI 0.45-0.65)和更低的重大出血风险(HR 0.67;95%CI 0.54-0.84)相关,且在诱发性VTE与非诱发性VTE患者中结果一致。
要点
- 阿哌沙班较华法林与更低的复发性VTE风险相关(HR 0.54;95%CI 0.45-0.65)。
- 阿哌沙班较华法林与更低的重大出血风险相关(HR 0.67;95%CI 0.54-0.84)。
- 上述结果在诱发性VTE和非诱发性VTE患者中保持一致。
核心结论
- 在真实世界中,VTE患者使用阿哌沙班较华法林与更低的复发性VTE和重大出血风险相关,扩展了随机临床试验的结果。
研究设计与样本
- 回顾性队列分析,数据来自商业和Medicare补充数据库,数据覆盖期为2014—2017年。
- 纳入诊断为VTE且为阿哌沙班或华法林新使用者的患者,采用倾向评分1:4匹配控制混杂。
- 采用Cox比例风险模型获得风险比(HR)和95%置信区间(CI)。
- 在诱发性VTE与非诱发性VTE患者中评估治疗效应的异质性。
主要发现
- 倾向评分匹配后共纳入36,907例患者,其中阿哌沙班8,094例、华法林28,813例。
- 阿哌沙班较华法林与更低的复发性VTE风险相关(HR,0.54;95% CI,0.45-0.65)。
- 阿哌沙班较华法林与更低的重大出血事件风险相关(HR,0.67;95% CI,0.54-0.84)。
- 上述结果在诱发性VTE和非诱发性VTE患者中保持一致。
临床怎么用
- 对于VTE患者的抗凝选择,该真实世界研究支持阿哌沙班较华法林具有更低的复发性VTE和重大出血风险。
- 研究结果可延伸至诱发性VTE患者等特定VTE亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Compared with conventional therapy (enoxaparin followed by warfarin), the direct-acting oral anticoagulant apixaban is thought to offer similar protection against recurrent venous thromboembolism (VTE) with lower bleeding risk. However, evidence regarding the heterogeneity of treatment effect from real-world data is lacking. The study described here aimed to compare the effectiveness and safety of use of apixaban versus warfarin in patients with VTE. METHODS: We conducted a retrospective cohort analysis of commercial and Medicare supplemental databases (data coverage period, 2014-2017) among patients with a diagnosis of VTE who were new users of apixaban or warfarin. We controlled for confounding using propensity score [PS] 1:4 matching. Cox proportional hazard models were used to obtain hazard ratios (HRs) and 95% confidence intervals (CIs). Heterogeneity of treatment effect was assessed among patients with provoked VTE versus unprovoked VTE. RESULTS: After PS matching, a total of 36,907 patients were included in the cohort (n = 8,094 apixaban users and n = 28,813 warfarin users). In Cox regression models, the use of apixaban versus warfarin was associated with lower risks of recurrent VTE (HR, 0.54; 95% CI, 0.45-0.65) and major bleeding events (HR, 0.67; 95% CI, 0.54-0.84); these results remained consistent in patients with provoked VTE and those with unprovoked VTE. CONCLUSION: This population-based analysis of patients with VTE extends results of randomized clinical trials indicating lower risks of development of recurrent VTE and major bleeding events with use of apixaban versus warfarin in real-world settings. The observed benefits of apixaban extended to selected subgroups of the VTE population, including patients with provoked VTE.
引用
- Dawwas GK, Smith SM, Dietrich E, et al. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. Am J Health Syst Pharm. 2020. PMID: 31974557. doi:10.1093/ajhp/zxz307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。